Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge

Joo-Youn Cho, Tsutomu Matsubara, Dong Wook Kang, Sung-Hoon Ahn, Kristopher W. Krausz, Jeffrey R. Idle, Hans Luecke, and Frank J. Gonzalez

Laboratory of Metabolism,* Center for Cancer Research, National Cancer Institute, and Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; and Institute of Pharmacology, Charles University, First Faculty of Medicine, Prague, Czech Republic

Abstract  Farnesoid X receptor (FXR) is a nuclear receptor that regulates genes involved in synthesis, metabolism, and transport of bile acids and thus plays a major role in maintaining bile acid homeostasis. In this study, metabolomic responses were investigated in urine of wild-type and Fxr-null mice fed cholic acid, an FXR ligand, using ultraperformance liquid chromatography (UPLC) coupled with electrospray time-of-flight mass spectrometry (TOFMS). Multivariate data analysis between wild-type and Fxr-null mice on a cholic acid diet revealed that the most increased ions were metabolites of p-cresol (4-methylphenol), corticosterone, and cholic acid in Fxr-null mice. The structural identities of the above metabolites were confirmed by chemical synthesis and by comparing retention time (RT) and/or tandem mass fragmentation patterns of the urinary metabolites with the authentic standards. Tauro-3α,6,7α,12α-tetrol (3α,6,7α,12α-tetrahydroxy-5β-cholestan-26-oic acid), one of the most increased metabolites in Fxr-null mice on a CA diet, is a marker for efficient hydroxylation of toxic bile acids possibly through induction of Cyp3α11. A cholestatic model induced by lithocholic acid revealed that enhanced expression of Cyp3α11 is the major defense mechanism to detoxify cholestatic bile acids in Fxr-null mice. These results will be useful for identification of biomarkers for cholestasis and for determination of adaptive molecular mechanisms in cholestasis.—Cho, J. Y., T. Matsubara, D. W. Kang, S. H. Ahn, K. W. Krausz, J. R. Idle, H. Luecke, and F. J. Gonzalez. Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J. Lipid Res. 2010. 51: 1063–1074.

Supplementary key words  adaptive response • cholic acid • corticosterone • Cyp3α11 • farnesoid X receptor • lithocholic acid • metabolomics • p-cresol

This work was supported by the National Cancer Institute Intramural Research Program. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. This work was also supported by Grant A03001 (J.Y.C.) from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea and by a grant for collaborative research (J.R.I.) from the United States Smokeless Tobacco Company.

Published, JLR Papers in Press, November 9, 2009
DOI 10.1194/jlr.M002923

The farnesoid X receptor (FXR; NR1H4) is a nuclear receptor that is activated by a number of bile acids including cholic acid, chenodeoxycholic acid, and lithocholic acid. Activated FXR forms a heterodimer with retinoid X receptors (RXR; NR1B) and binds its response elements usually located upstream of FXR target genes (1, 2). FXR regulates genes involved in synthesis, metabolism, and transport of bile acids in liver and gut, thereby maintaining bile acid homeostasis. Bile acids are produced from cholesterol in liver by bile acid synthetic enzymes, such as CYP7A1 and CYP8B1 (3), and are excreted into bile through canalicular bile acid transporters, such as bile salt export pump (BSEP) and MRP2 (4). However, under the condition of excessive bile acid loading such as in experimental cholestasis in mice, FXR is strongly activated by bile acids, downregulates the expression of Cyp7A1 and Cyp8B1, upregulates bile acid transporters, following which serum and liver bile acid levels are decreased (5).

The critical role of FXR in bile acid homeostasis was established using mice with targeted disruption of Fxr (Fxr-null mice) (6). Fxr-null mice, under conditions of bile acid loading such as cholic acid feeding and common bile duct ligation, had increased serum and liver bile acid levels and decreased fecal bile acid excretion because of reduced expression of the bile acid export pump BSEP (6). In addition, excretion of urinary bile acids was increased in Fxr-null mice fed diets containing 1% cholic acid, suggest-

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; CA, cholic acid; CAR, constitutive androstane receptor; CYP, cytochrome P450; DHODHA, 11β,20-dihydroxy-3-oxopreg-4-en-21-ol acid; FXR, farnesoid X receptor; HDOPHA, 11β-hydroxy-5,20-dioxopreg-4-en-21-ol acid; LCA, lithocholic acid; MS/MS, tandem mass spectrometry; OPLS, orthogonal partial least squares; PCA, principal components analysis; PLS-DA, partial least-squares discriminant analysis; PPARα, peroxisome proliferator-activated receptor α; PXR, pregnane X receptor; qPCR, quantitative real-time polymerase chain reaction; RT, retention time; TOFMS, time-of-flight mass spectrometry; UPLC, ultra-performance liquid chromatography.
ing that the metabolic pathways of controlling bile acid levels might be altered in Fxr-null mice (6). Recently, an adaptive response to bile acids in Fxr-null mice was reported. Loss of FXR leads to increased susceptibility to bile acid-induced liver injury and results in adaptive changes of genes involved in regulation of basolateral bile acid uptake, bile acid metabolism/detoxification, and alternative basolateral bile acid secretion in an FXR-independent manner (7, 8).

Metabolomics, the global approach for identification and quantification of metabolites in a living system or biological sample has been mostly performed using nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS) combined with various multivariate data analyses (9). Recently, robust metabolomic methods using the high resolution capability of ultra-performance liquid chromatography (UPLC) coupled with the accurate mass determination of time-of-flight (TOF) MS were developed for detection and characterization of small organic molecules in complex biological matrices (10). A recent metabolomics study, combined with a genetically modified knockout mouse, has revealed that activation of peroxisome proliferator-activated receptor α (PPARα) affects the metabolism of tryptophan, corticosterone, and fatty acids, and that novel steroid metabolites, 11β-hydroxy-3,20-dioxopregn-4-en-21-oic acid (HDOPA) and 11β,20-dihydroxy-3-oxopregn-4-en-21-oic acid (DHOPA), in urine can be biomarkers for activation of PPARα (11). More recently, a metabolomics study on the activation of pregnane X receptor (PXR) was performed using urine from Fxr-null mice and their congenic wild-type counterparts treated with the PXR ligand, pregnenolone 16α-carbonitride (12). A novel vitamin E metabolite, γ-CEHC glucoside, and α-CEHC glucuronide were strongly decreased upon activation of PXR and might serve as biomarkers for PXR activation. Thus, metabolomics revealed PXR-activated metabolic pathways associated with vitamin E metabolism (12). These studies highlight that metabolomics can be useful to identify small molecule signatures for gene deficiency and activation of nuclear receptors and/or their pathophysiological stimuli.

In the present study, altered metabolomic responses were investigated in urine of Fxr-null mice administered cholic acid compared with wild-type mice. UPLC-TOFMS coupled with multivariate data analyses were used to distinguish between the urinary metabolites in Fxr-null and wild-type mice on the CA diet. The structure of novel metabolites was identified and those metabolites were quantified using synthetic standards. This study further revealed adaptive molecular mechanisms for activation of alternate metabolic pathways in the cholestatic Fxr-null mouse.

**EXPERIMENTAL PROCEDURES**

**Reagents**

Standards for taurocholate, tauro-β-muricholate and reagents for synthesis were purchased from Sigma (St. Louis, MO). HDOPA and DHOPA were purchased from Anbilaunch consult-

ting (San Meteo, CA). HPLC-grade solvents (acetonitrile, methanol, and water) were purchased from Fisher Scientific (Hampton, NH).

**Animals, diets, and sample collection**

Fxr-null mice and the background matched wild-type mice generated as reported previously (6) were maintained under a standard 12-h light/12-h dark cycle with water and a normal diet (NIH-31) provided ad libitum. Groups of 8- to 12-week-old male mice were put on a synthetic purified diet (AIN-93G, Bio-Serv) at day 5 before treatment and maintained with water and the same diet ad libitum. The CA diet and LCA diet consisted of the control diet (AIN-93G) supplemented with 1% (w/w) CA and 0.6% (w/w) lithocholic acid, respectively. Fxr-null and wild-type mice were fed the CA diet or control diet for 7 days and the LCA diet or control diet for 4 days. Urine samples were collected from mice placed individually in metabolic cages for 24 h, before treatment and on day 6 of CA treatment or day 3 of LCA treatment. All urine samples were stored at –80°C until analyzed. At the end of the study, animals were killed, and serum and liver tissue were collected and frozen at –80°C for further analysis. Protocols for all animal studies were approved by the National Cancer Institute Animal Care and Use Committee and were carried out in accordance with the guidelines of Institute of Laboratory Animal Resources.

**Serum chemistry**

Serum was prepared by centrifugation at 8,000 rpm for 10 min and the catalytic activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were measured in serum. Briefly, 2 μl of serum was mixed with 200 μl of ALT or ALP assay buffer (Catachem, Bridgeport, CT) in a 96-well microplate and monitored at 340 nm or 405 nm for 10 min at 37°C. Serum corticosterone levels were determined using a Corticosterone EIA Kit (Cayman Chemical Co., Ann Arbor, MI) according to the manufacturer’s instruction.

**UPLC-TOFMS analyses**

Urine aliquots were diluted with 4 vols of 50% acetonitrile and centrifuged at 18,000 g for 20 min at 4°C to remove particles and proteins. The aliquots (5 μl) were injected into a reverse-phase 50 × 2.1 mm ACQUITY® 1.7-μm BEH C18 column (Waters Corp., Milford, MA) using an ACQUITY® UPLC system (Waters) with a Q-TOF Premier® (Waters), operating in either negative ion (ESI−) or positive ion (ESI+) electrospray ionization modes. The capillary and sampling cone voltages were set to 3000 and 30 V, respectively. The desolvation gas flow was set to 650 L/h and the temperature was set to 350°C. The cone gas flow was 50 L/h, and the source temperature was 120°C. To maintain mass accuracy, sulfadimethoxine ([M-H]− 399.0658) at a concentration of 250 pg/μl in 50% acetonitrile was used as a lock mass and injected at a rate of 30 μl/min. Data were acquired in centroid mode from 50 to 800 m/z in MS scanning. Tandem MS collision energy was scanned from 5 to 35 V.

**Data processing and multivariate data analysis**

Centroided and integrated chromatographic mass data from 50 to 800 m/z were processed by MarkerLynx® (Waters) to generate a multivariate data matrix. Pareto-scaled MarkerLynx matri-
ces including information on sample identity were analyzed by principal components analysis (PCA) and partial least-squares discriminant analysis (PLS-DA) using SIMCA-P+ 12 (Umetrics, Kinnelon, NJ). To determine which ions contribute to the difference between wild-type (y = 0) and Fxr-null (y = 1) mice of the CA-fed group, orthogonal partial least squares (OPLS) was used. The loadings scatter S-plots and the contribution lists were used to describe the candidate markers that were significantly different between wild-type and Fxr-null mice of CA-fed group.

Identification of metabolites

To identify the structure of high-contribution score metabolites, elemental compositions were generated with MassLynx® (Waters) based on the exact masses of the top twelve ions. To confirm the identities of markers, authentic standards at 5–20 μM in 50% acetonitrile were compared with the urine sample on the condition of MS/MS fragmentation with collision energy ramping from 15 to 35 V. Therefore, the MS/MS fragmentation spectrum of putative urinary metabolites was shown to be identical to that of the authentic standards.

Synthesis of 3-p cresol sulfate and glucuronide

3-p Cresol sulfate was prepared by treating 3-p cresol with chlorosulfonic acid in methylene chloride. To synthesize 3-p cresol glucuronide, 3-p cresol was reacted with tetraacetylglucuronyl trichloroimidate in the presence of boron trifluoride diethyl etherate in methylene chloride to afford 3-p cresol tetaacetylglucuronyl glucuronide (13). The product was hydrolyzed with 2M potassium hydroxide in methanol to obtain 3-p cresol glucuronide.

Synthesis of bile acid metabolites

Synthesis of (3a,6α,β,7α,12α)-tetrahydroxy-5β-cholic aci ds (4 epimers) have been reported (14). Synthesis of 3a,7β,12α,6α-tetrahydroxy-5β-cholic acid also followed this method. All stereoisomeric bile acids were synthesized from cholic acid. Taurine conjugates of 5β-cholic acids were synthesized by two-step reactions (15, 16). The first step was to prepare pentfluorophenyl esters where 5β-cholic acids reacted with pentfluorophenol in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in methylene chloride and a catalytic amount of N,N-dimethylformamide in methylene chloride. The second step was the reaction of 5β-cholic acid pentfluorophenyl esters and taurine in 1,8-diazabicyclo[5,4,0]undec-7-ene as a base in methylene chloride to synthesize taurine conjugates of bile acids. Although most of 5β-cholic acid taurine conjugates are very polar compounds, they can be purified by a general silica gel column chromatography method eluting with gradient of 5–25% methanol in methylene chloride. To isolate taurine conjugates by this general column chromatography method, 1% acetic acid was added to the eluting solvent. All 5β-cholic acids and their taurine conjugates have good solubility in water and methanol.

Quantification of urinary metabolites

QuanLynx® (Waters) was used to quantify urinary creatinine, HDOPA, DHOPA, taurocholate, tauro-7-epicholate, and tauro-3,6,7,12-tetrol from their peak areas. One μM of dehydrocholate ([M+H] + 401,2330) was included as an internal standard. Calibration curves were constructed from 50 to 1000 μM of creatinine ([M+H] + 114,0670) and from 1 to 100 μM of HDOPA ([M+H] + 359,1843), DHOPA ([M+H] + 361,2908), taurocholate ([M+H] + 514,2831 and RT 5.5 min), tauro-7-epicholate ([M+H] + 514,2822 and RT 5.0 min) and tauro-3,6,7,12-tetrol ([M+H] + 530,2779). The concentration of each analyte in mouse urine was determined from the calibration curves using linear regression analysis. All determined correlation coefficients were >0.95 for each analyte, and the resultant concentrations were expressed as μmol/mmol creatinine (normalized).

Gene expression analysis

Quantitative real-time PCR (qPCR) was performed using cDNA generated from 1 μg total mRNA SuperScript II Reverse Transcriptase kit (Invitrogen, Carlsbad, CA). Primers were designed for qPCR using the Primer Express software (Applied Biosystems, Foster City, CA) based on GenBank sequence data: Cyp3a11: forward 5’-ttctgctctcataaaaccgc-3’; reverse 5’-gggggagaagc-aagctctca-3’. Cyp2b10: forward 5’-tcttgccgccgtctgcag-3’; reverse 5’-ggctggagataggtcctag-3’ and Altern: forward 5’-ttcttgcagcctct-tctgt-3’, reverse 5’-agggggagatagccgc-3’. qPCR reactions were performed with the cDNA, the primer sets and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and demonstrated by an Applied Biosystems Prism 7900HT Sequence Detection System. Relative mRNA levels were calculated by the comparative threshold cycle method using β-actin (Actb) as the internal control.

Statistical analysis

Each group consisted of 6–12 animals for this study. All values are expressed as the means ± SD. Statistical analysis was performed by two-way ANOVA combined with Bonferroni posttests using Prism 5 (GraphPad Software Inc., San Diego, CA). Correlations of relative Cyp3a11 levels and relative abundance of taurocholate or ALT activity were calculated using Pearson correlation tests (Prism 5). A P value of less than 0.05 was considered statistically significant.

RESULTS

Phenotypes of Fxr-null mice

Male wild-type and Fxr-null mice fed a control diet showed no significant differences in body weight, liver-to-body weight ratio, and serum ALP activity, and serum ALT activity (Table 1). However, after feeding 1% CA for 7 days, Fxr-null mice exhibited more severe body weight loss, higher liver-to-body weight ratios, and higher serum ALT activity than wild-type mice (Table 1). These phenotypes are similar with those previously reported for wild-type and Fxr-null mice after feeding CA (17). In contrast, the typical diagnostic hepatotoxicity marker, serum ALT activity, was two-fold higher in Fxr-null mice than in wild-type mice fed control diet but was not significantly changed between Fxr-null and wild-type mice.

| Marker | Wild-Type Mice | Fxr-null mice | CA-Fed | Wild-Type Mice | Fxr-null mice |
|--------|----------------|--------------|--------|----------------|--------------|
| BW (%) | 101.2 ± 2.7 | 102.7 ± 1.6 | 90.7 ± 8.9 | 73.3 ± 4.16 |  |
| LW/BW ratio | 3.92 ± 0.21 | 3.79 ± 0.12 | 3.61 ± 0.45 | 5.08 ± 0.46 |  |
| ALT (IU/l) | 71.7 ± 20.1 | 141.4 ± 62.8 | 1240 ± 1110 | 1810 ± 625 |  |
| ALP (IU/l) | 163 ± 18.2 | 221 ± 102 | 165 ± 58.0 | 456 ± 91.0 |  |

Comparison of diagnostic markers between wild-type and Fxr-null mice in either control or cholic acid-treated groups (n = 4–12). Values are means ± SD. ALP, alkaline phosphatase; ALT, alanine aminotransferase; BW, body weight; FXR, farnesoid X receptor; LW, liver weight.

P < 0.01 compared with wild-type mice.

P < 0.001 compared with wild-type mice.

Table 1. Changes in body weight, liver-to-body weight ratio, and liver toxicity
fed CA, which suggested that Fxr-null mice under bile acid-loading conditions exhibited FXR-dependent cholestasis, but showed similar sensitivity to bile acid-induced hepatotoxicity compared with CA fed wild-type mice.

**Metabolomic analysis of mouse urine**

Urine samples for 0–24 h were collected before and after six days of CA feeding and analyzed by UPLC-TOFMS operating in both positive and negative ionization modes. Bile acids showed several fragment ions derived from only one bile acid in positive ion mode and thus multivariate data analysis was performed on the data matrix from the negative ionization mode. A large data matrix containing approximately 6000 ions was produced by MarkerLynx and subjected to both PCA and PLS-DA multivariate data analyses. Unsupervised PCA yielded a good separation of the data sets from the control and CA-fed groups in wild-type and Fxr-null mice, with fitness ($R^2$ value) of 0.52 and prediction power ($Q^2$ value) of 0.28 (data not shown). A supervised PLS-DA model with six components successfully discriminated the differences between all four groups of mice, having cumulative fitness ($R^2_X$ and $R^2_Y$ values) of 0.65 and 0.96, respectively, and cumulative prediction power ($Q^2$ value) of 0.80. Fig. 1A shows a PLS-DA scores plot providing a clear separation between wild-type (+/+) and Fxr-null (-/-) mice of CA-fed groups in component 1 (Y-axis) but not in the control diet group. This result revealed that more specific metabolic phenotypes were changed in Fxr-null mice than in wild-type mice by CA loading. After OPLS analysis of wild-type and Fxr-null mice in the CA-fed groups, a loadings S-plot showed ions with the highest confidence and greatest contribution to separation between wild-type and Fxr-null mice in the CA-fed groups (Fig. 1B). The significant ions increased in Fxr-null mice after CA loading were in the upper-right quadrant and those decreased were in the lower-left quadrant. The increased negative ions were labeled with a number from 1 to 12 according to the highest confidence and greatest contribution to separation between wild-type and Fxr-null mice in CA-fed groups in Fig. 1B. Three types of metabolites, specifically p-cresol, corticosterone, and cholic acid metabolites, were confirmed from the data (Table 2). To identify the structure of the above ions, accurate mass values of each ion was used for chemical formula calculations using elemental composition and mass-based searches in various database/literature were performed. Both 187.0060 (1; [M-H]_-) and 397.0009 (9; [2M-2H+Na]_-) ions correspond to p-cresol sulfate, and the 283.0812 (3; [M-H]_-) ions correspond to p-cresol sulfate.
ion corresponds to \( p \)-cresol glucuronide. Generation of the isomeric \( o \)-cresol and \( m \)-cresol sulfates in situ by the sultation of \( o \) and \( m \)-cresol with fuming sulfuric acid revealed that the three isomeric sulfates could not be resolved by UPLC and that they had virtually identical MS/MS spectra (data not shown). Accordingly, urines were hydrolyzed with 5M HCl at 100°C, neutralized, subjected to MS spectra (data not shown). Accordingly, urines were hydrolyzed with 5M HCl at 100°C, neutralized, subjected to MS spectra (data not shown). Accordingly, urines were hydrolyzed with 5M HCl at 100°C, neutralized, subjected to MS spectra (data not shown). Accordingly, urines were hydrolyzed with 5M HCl at 100°C, neutralized, subjected to MS spectra (data not shown).

**TABLE 2. Summary of negative metabolite ions showing significant increase in urine concentration of CA-fed Fxr-null mice**

| Ion Rank | RT (min) | Mass (m/z) | Identity                      | Empirical Formula        | Mass Error (ppm) | Fold Change (Fxr-null/WT) |
|----------|----------|------------|-------------------------------|--------------------------|------------------|--------------------------|
| p-Cresol metabolites |          |            |                               |                          |                  |                          |
| 1        | 3.41     | 187.006    | \( p \)-Cresol sulfate        | C7H8O4S                  | 2.5              | 5                        |
| 3        | 3.53     | 283.0812   | \( p \)-Cresol glucuronide    | C13H16O7                 | 2.0              | 8                        |
| 9        | 3.40     | 397.0000   | \( p \)-Cresol sulfate_dimer+Na| C14H16O8S2Na             | 4.6              | 9                        |
| Corticosterone metabolites |        |            |                               |                          |                  |                          |
| 4        | 5.29     | 361.2008   | DHOPA                         | C21H30O6                 | 1.9              | 18                       |
| 5        | 5.39     | 359.1843   | HDOPA                         | C21H28O5                 | 4.4              | 50<                      |
| 6        | 4.66     | 377.1943   | Hydroxylated DHOPA\(^{a}\)    | C21H30O6                 | 5.5              | 50<                      |
| 10       | 4.54     | 375.1799   | Hydroxylated HDOPA\(^{a}\)    | C21H28O6                 | 2.3              | 50<                      |
| Cholic acid metabolites |          |            |                               |                          |                  |                          |
| 2        | 4.79     | 530.2779   | Tauro-3\(\alpha\),6,7a,12α-tetrol | C26H45N08S              | 1.6              | 50<                      |
| 7        | 5.50     | 514.2831   | Taurocholate                   | C26H45N07S               | 1.5              | 5                        |
| 8        | 5.37     | 569.3306   | Cholate glucoside\(^{a}\)     | C30H50O10                | 3.5              | 12                       |
| 11       | 5.00     | 514.2822   | Tauro-7-epicholate             | C26H45N07S               | 3.2              | 50<                      |
| 12       | 5.15     | 676.3354   | Taurocholate glucoside\(^{a}\) | C32H55N012S             | 1.9              | 50<                      |

CA-fed Fxr-null mice compared with CA-fed wild-type mice (n = 12). Conditions for UPLC-TOFMS analysis are described in “Experimental Procedures.” Ion rank from a loading S-plot of OPLS analysis showed the rank of ions with the highest confidence and greatest contribution to separation between wild-type and Fxr-null mice. Ion rank is the same as labeling of ions in Fig. 1B. Fold change equals the fold increase in the level observed in Fxr-null mice group compared with wild-type mice group. CA, cholic acid; FXR, farnesoid X receptor; RT, retention time; TOFMS, time-of-flight mass spectrometry; UPLC, ultra-performance liquid chromatography; WT, wild type.

\(^{a}\)Structural identities of these metabolites were not elucidated.

**Identification and quantification of glucocorticoid metabolites**

To identify the structure of hydroxylated HDOPA and DHOPA, authentic compounds of 19-hydroxylated HDOPA and 19-hydroxylated DHOPA were synthesized and tandem MS fragmentation was performed. The patterns of MS/MS spectra between the synthetic compounds and the hydroxylated metabolites in mouse urine were different (data not shown), suggesting that the hydroxylated HDOPA and DHOPA is not 19-hydroxyl HDOPA and 19-hydroxyl DHOPA. The identities of HDOPA and DHOPA were established by comparison of MS/MS frag-
Fxr-null mice showed a robust increase in corticosterone level after treatment with the CA diet (changed 24.0 ± 8.3 to 149 ± 76 ng/ml, P < 0.01). On the other hand, wild-type mice did not exhibit a significant change in corticosterone levels (changed 13.0 ± 7.0 to 29.0 ± 17.0 ng/ml).

Identification of cholic acid metabolites

Authentic cholic acid metabolites were required for elucidating structure. Tauro-3α,7β,12α-trihydroxycholate (tauro-7-epicholate) and 4 epimers of tauro-3α,6(α/β),7(α/β),12α-tetrahydroxycholate were synthesized as described in "Experimental Procedures." However, two novel metabolites, cholate glucoside (C30H50O10, mass error = 3.5 ppm) and taurocholate glucoside (C32H55NO12S, mass error = 3.5 ppm) were determined in serum (Fig. 3E). Indeed, Fxr-null mice showed a robust increase in corticosterone level after treatment with the CA diet (changed 24.0 ± 8.3 to 149 ± 76 ng/ml, P < 0.01). On the other hand, wild-type mice did not exhibit a significant change in corticosterone levels (changed 13.0 ± 7.0 to 29.0 ± 17.0 ng/ml).

Identification of cholic acid metabolites

Authentic cholic acid metabolites were required for elucidating structure. Tauro-3α,7β,12α-trihydroxycholate (tauro-7-epicholate) and 4 epimers of tauro-3α,6(α/β),7(α/β),12α-tetrahydroxycholate were synthesized as described in "Experimental Procedures." However, two novel metabolites, cholate glucoside (C30H50O10, mass error = 3.5 ppm) and taurocholate glucoside (C32H55NO12S, mass error = 3.5 ppm) were determined in serum (Fig. 3E). Indeed, Fxr-null mice showed a robust increase in corticosterone level after treatment with the CA diet (changed 24.0 ± 8.3 to 149 ± 76 ng/ml, P < 0.01). On the other hand, wild-type mice did not exhibit a significant change in corticosterone levels (changed 13.0 ± 7.0 to 29.0 ± 17.0 ng/ml).
Metabolomics in Fxr-null mice

Acid metabolites are too stable in negative ion mode to generate their tandem mass spectra (Fig. 4). Taurocholate and tauro-7-epicholate have identical m/z ([M-H]− = 514.283) but separable retention time, i.e., 5.39 min (Fig. 4A) and 4.97 min (data not shown), respectively. Among the urinary ions with 514.283 m/z ([M-H]−), Peak a had a 4.97 min retention time and was revealed to be identical to error = 1.9 ppm), could not be synthesized and confirmed by UPLC-MS/MS.

The identities of tauro-3α,7α,12α-trihydroxycholate (taurocholate), tauro-7-epicholate, and tauro-3α,6,7α,12α-tetrahydroxycholate (tauro-3α,6,7α,12α-tetrol) were confirmed by comparison of retention time from authentic compounds and the urinary constituent because cholic acid metabolites are too stable in negative ion mode to generate their tandem mass spectra (Fig. 4). Taurocholate and tauro-7-epicholate have identical m/z ([M-H]− = 514.283) but separable retention time, i.e., 5.39 min (Fig. 4A) and 4.97 min (data not shown), respectively. Among the urinary ions with 514.283 m/z ([M-H]−), Peak a had a 4.97 min retention time and was revealed to be identical to
tauro-7-epicholate. Peaks b and c in Fig. 4A were confirmed with standard compounds of tauro-3α,6α,7β-trihydroxycholate (tauro-β-muricholate) and taurocholate, respectively. Among the four epimers of tauro-3α,6α,7α,12α-tetrol synthesized, both tauro-3α,6α,7α,12α-tetrol and tauro-3α,6β,7α,12α-tetrol had identical retention times (4.69 min) under the chromatographic conditions employed. Peak d, the highest among the ions in the extracted chromatogram ([M-H]⁻ = 530,278) of mouse urine sample, had identical retention time (4.69 min) with the above authentic compounds. Therefore, the identity of taurotetrol that was greatly increased in Fxr-null mice after CA feeding was tauro-3α,6α,7α,12α-tetrol (Fig. 4B). The other two epimers, tauro-3α,6α,7β,12α-tetrahydroxycholate and tauro-3α,6β,7β,12α-tetrahydroxycholate did not show the identical retention time to the other peaks extracted with 530,278 m/z ([M-H]⁻).

Quantification of cholic acid metabolites

The concentrations of taurocholate, tauro-7-epicholate, and tauro-3α,6,7α,12α-tetrol as well as creatinine were measured in each urine sample using dehydroxycholate as an internal standard and expressed as µmol/mmol creatinine. Urinary concentrations of taurocholate, tauro-7-epicholate and tauro-3α,6,7α,12α-tetrol were undetectable in both wild-type and Fxr-null mice fed control diet (Fig. 5). After feeding the CA diet, taurocholate concentrations were elevated to 46.4 ± 59.5 µmol/mmol creatinine in wild-type mice and to 139 ± 64.4 µmol/mmol creatinine in Fxr-null mice, which were statistically significantly different (P < 0.001). In contrast to undetectable concentration of tauro-7-epicholate and tauro-3α,6,7α,12α-tetrol in wild-type mice on the CA diet, their concentrations in Fxr-null mice on the CA diet was 82.8 ± 68.3 µmol/mmol creatinine for tauro-7-epicholate and 444 ± 322 µmol/mmol creatinine for tauro-3α,6,7α,12α-tetrol (Fig. 5B, C).

Hepatic gene expression

Metabolomic differences in urine between wild-type and Fxr-null mice after feeding the CA diet suggested that increased urinary metabolic phenotypes resulted from an adaptive response of Fxr-null mice to CA-induced toxicity through alteration of gene expression for metabolic enzymes. Specifically, the highly increased cholic acid metabolite in Fxr-null fed CA, tauro-3α,6,7α,12α-tetrol, was a 6-hydroxylated form of taurocholate, which suggested that bile acid-oxidation enzymes such as CYP3A11 and CYP2B10 were induced in Fxr-null mice (18). The hepatic expression of Cyp3a11, a representative PXR target gene, was elevated significantly by approximately 6-fold in Fxr-null mice fed both control and CA diets, compared with wild-type mice fed a control diet (data not shown). The hepatic expression of Cyp2b10, a representative constitutive androstane receptor (CAR) target gene, was elevated by approximately 10-fold and 4-fold in Fxr-null mice fed control and CA diets, respectively, compared with wild-type mice fed a control diet (data not shown), but these differences were not statistically significant. These expression levels for Cyp3a11 and Cyp2b10 were similar to a previous report (18).

Cholestatic hepatotoxicity model

Recent reports revealed that Fxr-null mice detoxify accumulating bile acids in the liver by enhanced hydroxylation
hydroxy bile acid ([M-H]^- = 530.278), which may be derived from LCA, was measured individually in addition to analysis of the relative Cyp3a11 level and serum ALT activity. A clear correlation (Pearson’s correlation coefficient, r = 0.63, P = 0.005) was observed between individual relative abundance of the taurotetratol and Cyp3a11 expression levels (Fig. 6A). The relative abundance of the taurotetratol was significantly 4.3-fold higher in Fxr-null than in wild-type mice (P = 0.009). In addition, relative Cyp3a11 expression levels in liver exhibited a significant increase by 3.8-fold in Fxr-null mice on the LCA diet compared with those in wild-type mice on LCA diet (P < 0.0001). Moreover, an inverse correlation (r = −0.85, P < 0.0001) was observed between ALT activity and relative CYP3A11 levels in liver of both wild-type and Fxr-null mice (Fig. 6B). Serum ALT activity was 4860 ± 1680 IU/L in wild-type mice and 1960 ± 1090 IU/L in Fxr-null mice on LCA diet (40% lower than wild-type mice, P = 0.0003). However, serum ALP activity, a typical diagnostic cholestatic marker, was not significantly different between wild-type and Fxr-null mice on LCA diet (569 ± 169 and 444 ± 195 IU/L, respectively). Taken together, these data suggested that Fxr-null mice eliminate the systemic and hepatic bile acid load more rapidly than wild-type mice by increasing the expression of CYP3A11, resulting in increased hydroxylation of bile acids and less hepatotoxicity than wild-type mice under LCA-induced cholestasis.

**DISCUSSION**

Global analyses of urinary metabolomes in Fxr-null mice compared with their wild-type littermates under conditions of CA loading revealed separation of three groups in a scores plot: control wild-type and Fxr-null mice; CA-fed wild-type mice; and CA-fed Fxr-null mice. These results suggest that CA feeding markedly changes urinary metabolites in Fxr-null mice and, to a lesser degree, in wild-type mice. OPLS analysis between wild-type and Fxr-null mice on the CA diet further showed that most of the increased ions were metabolites of p-cresol, corticosterone, and CA.

Urinary p-cresol comes from dietary polyphenols or tyrosine residues generated by intestinal microorganisms including Proteus vulgaris, Clostridium difficile, and unidentified species of Lactobacillus (20, 21). Urinary p-cresol was reported to be one of the dysbiosis markers, including benzoate, hippurate, phenylacetate, and hydroxybenzoate, which are associated with microbial overgrowth (22). More recently, metabolomics analysis revealed p-cresol sulfate as being unique to plasma samples of conventional mice compared with samples of germ-free mice (23). In this study, attenuated p-cresol conjugates after CA feeding suggested that oral administration of bile acids inhibits the intestinal microbial overgrowth (24). Specifically, CA feeding markedly attenuated urinary p-cresol metabolites in wild-type mice but to a lesser extent in Fxr-null mice, indicating that CA feeding substantially increases fecal bile acid excretion through induction of bile acid transporters in wild-type mice but to a lesser extent in Fxr-null mice, as
revealed in the fecal bile acid excretion rate documented in an earlier study (6).

A dramatic increase of urinary corticosterone metabolites HDOPA and DHOPA, as well as serum corticosterone, was observed only in cholestatic mice (i.e., Fxr-null mice fed CA for 7 days). In cholestatic animal models and humans, the hypothalamic-pituitary-adrenal axis was activated by endotoxin and cytokines, such as tumor necrosis factor-α, resulting in an elevation of plasma glucocorticoid concentration (25). Most of the corticosterone present in the blood is excreted into urine and feces as more polar metabolites of corticosterone through an intensive steroid metabolism in liver and gut (26), although there has been only limited information about metabolic pathways of glucocorticoids (27). Therefore, highly increased urinary excretion of HDOPA and DHOPA in acute cholestasis may result from secretion and extensive metabolism of corticosterone. Recently, HDOPA and DHOPA were reported as high-specific biomarkers for activation of PPARα (11). However, high levels of HDOPA and DHOPA in CA-fed Fxr-null mice may not be associated with activation of PPARα because the expression of PPARα-target genes such as Cpt1a and Gyp4a10 were not induced by CA feeding (data not shown). Furthermore, a previous study reported that bile acids interfere with transactivation of PPARα at least in part by impairing the recruitment of transcriptional coactivators (28). Hydroxylated metabolites of HDOPA and DHOPA were also highly increased in CA-fed Fxr-null mice to an extent similar to that observed with HDOPA and DHOPA. However, an increase of these hydroxylated metabolites were not found in urine from mice treated with the PPARα agonist Wy-14,643 (11). This result indicates that CA-fed Fxr-null mice have different metabolic pathways of corticosterone from PPARα-activated mice, possibly mediated by induction of hydroxylation by enzymes such as CYP3A11. However, further investigation should be performed to establish the specific metabolic pathways of corticosterone, HDOPA, and DHOPA in cholestatic mice.

The metabolomics data revealed various CA metabolites as potential markers of cholestasis: taurocholate; tauro-7-epicholate; tauro-3α,6,7α,12α-tetrol; cholate glucoside; and taurocholate glucoside. However, the structures of cholate glucoside and taurocholate glucoside could not be confirmed in this study, thus warranting further investigation. Tauro-7-epicholate and tauro-3α,6,7α,12α-tetrol were identified and quantified as a form of free bile acids in previous reports (18, 29, 30), but their structures in this study were confirmed by comparison with each synthetic conjugated compound. Because bile acids are generally too stable in negative ion mode to generate their tandem mass spectra, identification of structures was performed by comparison of retention time. Although this method is not ideal because of similar structures and similar retention times with each CA metabolite, three compounds with 514.283 m/z including taurocholate, tauro-7-epicholate, and tauro-β-muricholate could be distinguished using retention time. In the case of four epimers of tauro-3α,6(α/β),7(α/β),12α-tetrol synthesized in the present study, different retention times were observed between tauro-3α,6α,7β,12α-tetrol and tauro-3α,6β,7β,12α-tetrol, whereas tauro-3α,6α,7α,12α-tetrol and tauro-3α,6β,7α,12α-tetrol had identical retention times under the chromatographic conditions performed here. Nevertheless, tauro-3α,6(α/β),7α,12α-tetrols were observed in urine, plasma, bile or liver tissue of both Fxr-null mice and Bsep-null mice in previous studies (18, 29). The other taurotetrols, except for tauro-3α,6,7α,12α-tetrol, also existed in a
chromatogram extracted for 530.278 m/z, which may be hydroxylated forms of CA in positions other than the 6 position. Marschall et al. had revealed significantly enhanced hydroxylation at the 1β, 2β, 4β, 6α, 6β, 22, or 23 positions of CA in FXR-null mice with biliary obstruction (18). They also exhibited elevated expression of CYP3A11 in FXR-null mice as compared with wild-type mice with biliary obstruction. Human CYP3A4, a homolog to mouse CYP3A11, plays a role of hydroxylation of bile acids at the 6α and 6β positions (31, 32). Therefore, highly expressed CYP3A11 in cholestatic condition was involved in enhanced urinary excretion of hydroxylated bile acids including tauro-3α,6,7α,12α-tetrol.

Several previous reports have clearly demonstrated that induction of CYP3A expression enhances the formation of hydroxylated LCA and protects against severe liver damage induced by LCA (32, 33). In the present study, high expression of CYP3A11 and enhanced urinary excretion of tetrals in FXR-null mice under CA loading suggested that FXR-null mice had an adaptive defense mechanism to detoxify accumulating bile acids in the liver by enhanced hydroxylation probably catalyzed by CYP3A11. However, because wild-type mice under CA loading had increased expression of BSEP and enhanced biliary excretion of bile acids but did not show cholestasis, we could not prove the adaptive hepatoprotective effects against bile acid-induced liver damage in FXR-null mice using the CA loading model. Because LCA feeding induces segmental bile duct obstruction and destructive cholangitis in wild-type mice (34), we observed that serum ALT activity in wild-type mice was significantly higher than that in FXR-null mice using LCA-induced cholestatic mouse model, suggesting that FXR-null mice have a higher capacity to attenuate bile acid-induced hepatotoxicity than do wild-type mice. In addition, the correlation plot of relative abundance of taurotetrol or se- and 22, or 23 taurine conjugated hexosamines. J. Biol. Chem. 273–292. 12. Cho, J. Y., D. W. Kang, X. Ma, S. H. Ahn, K. W. Krausz, H. Luecke, J. R. Idle, and F. J. Gonzalez. 2009. Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J. Lipid Res. 50: 924–937. 13. Needs, P. W., and G. Williamson. 2001. Syntheses of daidzein-7-β-D-glucopyranosiduronic acid and daidzein-4′,7-β-D-glucopyranosiduronic acid. Carbohydr. Res. 330: 511–515. 14. Iida, T., I. Komatsubara, S. Yoda, J. Goto, T. Nambara, and F. C. Chang. 1990. Potential bile acid metabolites. 16. Synthesis of steriosomeric 3α,6,7,12α,14α,26α,27α,28,30-lactones and 3α,6,7,12α,26α,27α,30-lactone. J. Org. Chem. 56: 946–952. 15. Dayal, B. K., R. Rapole, G. Salen, S. Shefer, G. S. Tint, and S. R. Wilson. 1995. Microwave-induced rapid synthesis of bile-acid conjugates. Synlett. 89 – 92. 16. Guo, G. L., G. Lambert, M. Negishi, J. M. Ward, H. B. Brewer, Jr., S. A. Kliewer, F. J. Gonzalez, and C. J. Sinal. 2003. Complementary roles of farnesoid X receptor, pregnane X receptor, and consti-
tutive androstanone receptor in protection against bile acid toxicity. 
J. Biol. Chem. 278: 45062–45071.
18. Marschall, H. U., M. Wagner, K. Bodin, G. Zollner, P. Fickert, J. Gumhold, D. Silbert, A. Fuchsbichler, J. Sjovall, and M. Trauner. 2006. Fxr(−/−) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J. Lipid Res. 47: 582–592.
19. Hofmann, A. F. 2004. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 36: 703–722.
20. Martin, A. K., J. A. Milne, and P. Moberly. 1983. The origin of urinary aromatic compounds excreted by ruminants. 4. The potential use of urinary aromatic acid and phenol outputs as a measure of voluntary food intake. Br. J. Nutr. 49: 87–99.
21. Lord, R. S., and J. A. Bralley. 2008. Clinical applications of urinary organic acids. Part 2. Dysbiosis markers. Altern. Med. Rev. 13: 292–306.
22. Wikoff, W. R., A. T. Anfora, J. Liu, P. G. Schultz, S. A. Lesley, E. C. Peters, and G. Siaudzak. 2009. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA. 106: 3698–3703.
23. Lorenzo-Zuniga, V., R. Bartoli, R. Planas, A. F. Hofmann, B. Vinado, L. R. Hagey, J. M. Hernandez, J. Mane, M. A. Alvarez, V. Ausina, et al. 2003. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 37: 551–557.
24. Swain, M. G., and M. Maric. 1996. Tumor necrosis factor-alpha stimulates adrenal glucocorticoid secretion in cholestatic rats. Am. J. Physiol. 270: G987–G991.
25. Touma, C., N. Sachser, E. Mostl, and R. Palme. 2003. Effects of sex and time of day on metabolism and excretion of corticosterone in urine and feces of mice. Gen. Comp. Endocrinol. 130: 267–278.
26. Han, A., A. Marandici, and C. Monder. 1983. Metabolism of corticosterone in the mouse. Identification of 11 beta, 20 alpha-dihydroxy-5-oxo-4-pregnen-21-oic acid as a major metabolite. J. Biol. Chem. 258: 13703–13707.
27. Sinal, C. J., M. Yoon, and F. J. Gonzalez. 2001. Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids. J. Biol. Chem. 276: 47154–47162.